SCHEMBL5822902

SCHEMBL5822902

O=C(O)C(Cl)(CCl)COc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.46
MAPT P10636 1/20 0.44
RAB9A P51151 1/20 0.44
PKM P14618 1/20 0.41
PPARA Q07869 1/20 0.40
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PARP10 Q53GL7 1/20 0.39
ALDH1A1 P00352 3/20 0.38
RECQL P46063 1/20 0.38
CYP1A2 P05177 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
TSHR P16473 1/20 0.38
MAPK10 P53779 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MTNR1A P48039 1/20 0.38
MTNR1B P49286 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL10738326 0.95 MAPT (0.44) ALOX15MAPTRAB9APKMPPARA
SCHEMBL1019370 0.79 ALOX15 (0.50) ALOX15RAB9APKMPPARACYP2C9
SCHEMBL8468005 0.78 ALOX15 (0.48) ALOX15RAB9APKMPPARACYP2C9
SCHEMBL3465226 0.76 PPARA (0.47) ALOX15MAPTRAB9APKMPPARA
SCHEMBL11440739 0.72 KCNA3 (0.46) ALOX15PKMCYP2C9CYP2C19ALDH1A1
SCHEMBL11529053 0.72 ALOX15 (0.43) ALOX15MAPTRAB9APKMPARP10
SCHEMBL11191140 0.72 KCNA3 (0.50) ALOX15RAB9APKMCYP2C9CYP2C19
SCHEMBL5724626 0.72 PPARA (0.58) ALOX15PPARACYP2C9
SCHEMBL7805112 0.70 PPARA (0.49) ALOX15MAPTRAB9APKMPPARA
SCHEMBL8103778 0.70 ALOX15 (0.48) ALOX15PKMPPARACYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006058199-A1 METHODS OF MODULATING HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND PHARMACEUTICAL FORMULATIONS FOR THE SAME FAZIX CORPORATION (US) 2006-06-01 WO disclosed
US-20060111346-A1 Methods of modulating high-density lipoprotein cholesterol levels and pharmaceutical formulations for the same FAZIX CORPORATION. 2006-05-25 US disclosed
US-4826861-A MEDICAL BACTERICIDES OR FUNGICIDES ALBERT ROLAND, S.A. (FR) 1989-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111346-A1 Methods of modulating high-density lipoprotein cholesterol levels and pharmaceutical formulations for the same HDLBP, LDLR, CETP ALOX15 1739/4885MAPT 3110/4885RAB9A 3535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.